Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. With a market cap of $5 billion, it operates in the health care sector, aiming to address serious diseases through innovative therapies.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.06

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of $-1.28, missing estimates and resulting in a 3.78% increase in stock the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Focus on advancing clinical trials for its gene-editing therapies.
Commitment to improving operational efficiency.
Plans to expand partnerships for research and development.

Expectations

Wall Street Expectations

Analysts expect CRISPR to report a loss this quarter, with a consensus EPS of $-1.06 and revenue of $16 million. The market is watching closely for any signs of progress in its clinical programs.

Bull Case

If CRISPR can demonstrate significant advancements in its clinical trials, it could lead to increased investor confidence and a higher stock price.

Bear Case

Continued losses and failure to meet revenue expectations may lead to a decline in stock price, as investors grow concerned about the company's future viability.

Key Metrics to Watch

EPS

$-1.06

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$16M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRISPR's EPS meet or exceed the consensus estimate of $-1.06?

A better-than-expected EPS could boost investor confidence and positively impact the stock price.

What are the updates on CRISPR's clinical trials and revenue generation?

Insights into trial progress and revenue could significantly influence market perception and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for CRISPR to exceed revenue expectations due to recent advancements in its clinical trials.

Supporting Evidence

The company has a history of surprising on the upside, as seen in previous quarters.

Options are pricing a significant move, indicating that traders expect volatility that could favor a positive outcome.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against ongoing financial losses, making this quarter critical for future expectations.

Bull Confirmed If

An EPS of $-1.06 or better, coupled with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.50 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats EPS estimates and provides positive guidance, history suggests the stock could rise by around 3.6% on the first trading day.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may see limited movement as investors digest the information.

Miss

Should the company miss expectations, history suggests a potential decline of about 0.68% on the first trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and any new partnerships.
2Details on cost management strategies and operational efficiency improvements.
3Any commentary on market demand for CRISPR's therapies.
4Insights into future revenue projections and product pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.06

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$16M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1-2026, CRISPR reported an EPS of $-1.28, missing estimates and resulting in a 3.78% increase in stock the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Focus on advancing clinical trials for its gene-editing therapies.
Commitment to improving operational efficiency.
Plans to expand partnerships for research and development.

Expectations

Wall Street Expectations

Analysts expect CRISPR to report a loss this quarter, with a consensus EPS of $-1.06 and revenue of $16 million. The market is watching closely for any signs of progress in its clinical programs.

Bull Case

If CRISPR can demonstrate significant advancements in its clinical trials, it could lead to increased investor confidence and a higher stock price.

Bear Case

Continued losses and failure to meet revenue expectations may lead to a decline in stock price, as investors grow concerned about the company's future viability.

Key Metrics to Watch

EPS

$-1.06

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$16M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will CRISPR's EPS meet or exceed the consensus estimate of $-1.06?

A better-than-expected EPS could boost investor confidence and positively impact the stock price.

What are the updates on CRISPR's clinical trials and revenue generation?

Insights into trial progress and revenue could significantly influence market perception and future growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for CRISPR to exceed revenue expectations due to recent advancements in its clinical trials.

Supporting Evidence

The company has a history of surprising on the upside, as seen in previous quarters.

Options are pricing a significant move, indicating that traders expect volatility that could favor a positive outcome.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against ongoing financial losses, making this quarter critical for future expectations.

Bull Confirmed If

An EPS of $-1.06 or better, coupled with positive updates on clinical trials, would confirm the bull case.

Bear Confirmed If

An EPS worse than $-1.50 would confirm the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±26.4%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats EPS estimates and provides positive guidance, history suggests the stock could rise by around 3.6% on the first trading day.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may see limited movement as investors digest the information.

Miss

Should the company miss expectations, history suggests a potential decline of about 0.68% on the first trading day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and any new partnerships.
2Details on cost management strategies and operational efficiency improvements.
3Any commentary on market demand for CRISPR's therapies.
4Insights into future revenue projections and product pipeline developments.